A phase II study of tislelizumab plus chemotherapy in EGFR mutated advanced non-squamous NSCLC patients failed to EGFR TKI therapies: First analysis
文献类型：期刊论文
| 作者 | Han, B.1; Tian, P.2; Zhao, Y.3 ; Yu, X.4,5; Guo, Q.6; Yu, Z.7; Zhang, X.1; Li, Y.2; Chen, L.3; Shi, X.4,5
|
| 刊名 | ANNALS OF ONCOLOGY
 |
| 出版日期 | 2021-12-01 |
| 卷号 | 32 |
| ISSN号 | 0923-7534 |
| DOI | 10.1016/j.annonc.2021.10.167 |
| 资助项目 | BeiGene (Beijing), Co. Ltd. |
| WOS研究方向 | Oncology |
| 语种 | 英语 |
| 出版者 | ELSEVIER |
| WOS记录号 | WOS:000731051400151 |
| 资助机构 | BeiGene (Beijing), Co. Ltd. |
| 源URL | [http://ir.hfcas.ac.cn:8080/handle/334002/126442]  |
| 专题 | 中国科学院合肥物质科学研究院 |
| 作者单位 | 1.Shanghai Jiao Tong Univ, Resp Dept, Shanghai Chest Hosp, Shanghai, Peoples R China 2.Sichuan Univ, Dept Resp Med, West China Hosp, Chengdu, Peoples R China 3.Zhengzhou Univ, Dept Med Oncol, Affiliated Canc Hosp, Henan Canc Hosp, Zhengzhou, Peoples R China 4.Univ Chinese Acad Sci, Canc Hosp, Dept Med Oncol, Hangzhou, Peoples R China 5.Zhejiang Canc Hosp, Hangzhou, Peoples R China 6.Shandong Univ, Shandong Canc Hosp, Dept Med Oncol, Jinan, Peoples R China 7.Qingdao Univ, Affiliated Hosp, Dept Med Oncol, Qingdao, Peoples R China |
| 推荐引用方式 GB/T 7714 | Han, B.,Tian, P.,Zhao, Y.,et al. A phase II study of tislelizumab plus chemotherapy in EGFR mutated advanced non-squamous NSCLC patients failed to EGFR TKI therapies: First analysis[J]. ANNALS OF ONCOLOGY,2021,32. |
| APA | Han, B..,Tian, P..,Zhao, Y..,Yu, X..,Guo, Q..,...&Wang, J..(2021).A phase II study of tislelizumab plus chemotherapy in EGFR mutated advanced non-squamous NSCLC patients failed to EGFR TKI therapies: First analysis.ANNALS OF ONCOLOGY,32. |
| MLA | Han, B.,et al."A phase II study of tislelizumab plus chemotherapy in EGFR mutated advanced non-squamous NSCLC patients failed to EGFR TKI therapies: First analysis".ANNALS OF ONCOLOGY 32(2021). |
入库方式： OAI收割
来源：合肥物质科学研究院
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。